Search Results

Filter
  • 1-2 of  2 results for ""Breast Neoplasms drug therapy""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.

  • Authors : Yaghi M; Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, US. Electronic address: .; Bilani N

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology ; Carcinoma, Lobular*/Carcinoma, Lobular*/Carcinoma, Lobular*/drug therapy; Female

  • Source: Cancer treatment and research communications [Cancer Treat Res Commun] 2023; Vol. 34, pp. 100666. Date of Electronic Publication: 2022 Dec 10.Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942

Record details

×
Academic Journal

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

  • Authors : Becker MA; Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA. .; Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN, 55905, USA. .

Subjects: Drug Synergism*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacology ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy

  • Source: BMC cancer [BMC Cancer] 2016 Oct 20; Vol. 16 (1), pp. 814. Date of Electronic Publication: 2016 Oct 20.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

×
  • 1-2 of  2 results for ""Breast Neoplasms drug therapy""